Skip to main content

CLINICAL TRIAL article

Front. Med.
Sec. Intensive Care Medicine and Anesthesiology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1429109
This article is part of the Research Topic Novel Treatments For Cardiovascular Diseases By Targeting Inflammation, Oxidative Stress, and Cell Death View all articles

Heparanase inhibitor improves clinical study in patients with septic cardiomyopathy

Provisionally accepted
Di Chen Di Chen 1Hong-Lei Li Hong-Lei Li 1*Shitao Huang Shitao Huang 1*Zhongya Huang Zhongya Huang 1*Yibo Sun Yibo Sun 1*Li-Ping Liu Li-Ping Liu 2*
  • 1 The First clinical medical school of Lanzhou University, Lanzhou, China
  • 2 Departments of Emergency Critical Care Medicine, The First Hospital of Lanzhou University, The First clinical medical school of Lanzhou University, Lanzhou, China

The final, formatted version of the article will be published soon.

    Main content of the article:Septic cardiomyopathy (SCM) is a common and serious complication in patients with sepsis and septic shock. Due to its complex pathogenesis, there are currently no clear diagnostic criteria. Clinical treatment mainly focuses on correcting the underlying disease and providing symptomatic relief, with the mortality rate remaining high. This study aims to investigate the impact of low molecular weight heparin on the levels of Heparanase (HPA) in SCM patients and evaluate the clinical diagnostic value of HPA in SCM patients. The author likes the style of articles in this journal very much, and often reads many of them. I hope you can give me valuable comments

    Keywords: Heart function, Microcirculation, Septic cardiomyopathy, Heparanase inhibitor, Mitochondrial function

    Received: 07 May 2024; Accepted: 22 Jul 2024.

    Copyright: © 2024 Chen, Li, Huang, Huang, Sun and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Hong-Lei Li, The First clinical medical school of Lanzhou University, Lanzhou, China
    Shitao Huang, The First clinical medical school of Lanzhou University, Lanzhou, China
    Zhongya Huang, The First clinical medical school of Lanzhou University, Lanzhou, China
    Yibo Sun, The First clinical medical school of Lanzhou University, Lanzhou, China
    Li-Ping Liu, Departments of Emergency Critical Care Medicine, The First Hospital of Lanzhou University, The First clinical medical school of Lanzhou University, Lanzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.